While autoimmune diseases have been frequently found to coexist in the same patients, the co-occurrence of myasthaeniagravis and antiphospholipid antibody syndrome (APAS) has only been reported in eight cases. We present a case of a 46-year-old Filipina who developed ischaemic stroke while admitted at the neurocritical unit for myasthaenic crisis. She was successfully thrombolysed with intravenous recombinant tissue plasminogen activator (rTPA), given a regimen of intravenous Ig and a dose of cyclophosphamide prior to discharge. Extensive workup revealed APAS to be the aetiology of her stroke. Twenty-one months into her follow-up, she is doing well with a modified Rankin Score of 0. Our case suggests that rTPA followed by immunomodulators may be given safely in myasthaenic crisis patients who develop ischaemic stroke. We emphasise the importance of doing a comprehensive neurological evaluation in agitated patients in the critical care unit.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721000PMC
http://dx.doi.org/10.1136/bcr-2019-231239DOI Listing

Publication Analysis

Top Keywords

ischaemic stroke
12
myasthaenic crisis
12
antiphospholipid antibody
8
antibody syndrome
8
stroke patient
4
patient myasthaenic
4
crisis antiphospholipid
4
syndrome autoimmune
4
autoimmune diseases
4
diseases frequently
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!